Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Puttagunta Sailaja

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/28/2019

3. Issuer Name and Ticker or Trading Symbol

BiomX Inc. [PHGE]

(Last) (First) (Middle)

C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /

(Street)

NESS ZIONA, L3 7414002

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Options-Right to Buy	⁽¹⁾	12/5/2028	Common Stock Options	183946	$2.03	I	By SPB Consulting LLC ⁽⁴⁾
Common Stock Options-Right to Buy	⁽²⁾	12/5/2028	Common Stock Options	73579	$2.03	I	By SPB Consulting LLC ⁽⁴⁾
Common Stock Options-Right to Buy	⁽³⁾	3/29/2029	Common Stock Options	6051	$2.03	I	By SPB Consulting LLC ⁽⁴⁾

Explanation of Responses:
(1)	25% of these options shall vest on December 5, 2019 . Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 183,946 shares of common stock were unvested.
(2)	These options shall vest upon the achievement of specific performance-based milestones, as defined in the option grant. As of the reporting date, options to purchase 73,579 shares of common stock were unvested.
(3)	25% of these options shall vest on March 29, 2020. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 6,051 shares of common stock were unvested.
(4)	Options are held by SPB Consulting LLC. The reporting person is the sole member of SPB Consulting LLC and may be deemed the indirect beneficial owner of the securities held by SPB Consulting LLC.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Puttagunta Sailaja C/O BIOMX LTD. 7 PINHAS SAPIR ST., FLOOR 2 NESS ZIONA, L3 7414002			Chief Medical Officer